Walgreens January Sales Increase 3.7 Percent
February 05 2014 - 8:00AM
Business Wire
Walgreens (NYSE: WAG) (Nasdaq: WAG) had January sales of $6.39
billion, an increase of 3.7 percent from $6.17 billion for the same
month in fiscal 2013.
Total front-end sales increased 2.4 percent compared with the
same month in fiscal 2013, while comparable store front-end sales
increased 1.6 percent. Customer traffic in comparable stores
decreased 2.2 percent while basket size increased 3.8 percent.
Prescriptions filled at comparable stores decreased by 0.8
percent in January and decreased 0.4 percent on a calendar
day-shift adjusted basis. January 2014 had one additional Friday
and one fewer Tuesday compared with January 2013. These calendar
shifts negatively impacted prescriptions filled at comparable
stores by 0.4 percentage point.
Prescriptions filled at comparable stores were negatively
impacted by 0.8 percentage point due to fewer flu shots in the
month versus last year and were negatively impacted by 1.4
percentage points due to the lower incidence of flu in January
2014.
January pharmacy sales increased by 4.6 percent, while
comparable store pharmacy sales increased 3.7 percent and increased
by a calendar day-shift adjusted 4.1 percent. Calendar day shifts
negatively impacted pharmacy sales in comparable stores by 0.4
percentage point. Calendar day-shift adjusted comparable store
pharmacy sales were negatively impacted by 1.3 percentage points
due to generic drug introductions in the last 12 months, and were
negatively impacted by 0.5 percentage point due to fewer flu shots
in January versus last year. The lower incidence of flu negatively
impacted pharmacy sales by 1.1 percentage points. Pharmacy sales
accounted for 65.6 percent of total sales for the month.
Flu shots administered at pharmacies and clinics season to date
were more than 7.5 million versus nearly 6.9 million last year.
Sales in comparable stores increased by 2.9 percent in January.
Calendar day shifts negatively impacted total comparable sales by
0.3 percentage point, while generic drug introductions in the last
12 months negatively impacted total comparable sales by 0.9
percentage point.
Fiscal 2014 year-to-date sales for the first five months were
$31.92 billion, up 5.7 percent from $30.20 billion in the
comparable period in fiscal 2013.
Walgreens opened 12 stores during January, including three
relocations, and closed three.
On Jan. 31, Walgreens operated 8,678 locations in all 50 states,
the District of Columbia, Puerto Rico, Guam and the U.S. Virgin
Islands. That includes 8,206 drugstores, 139 more than a year ago,
including 60 net stores acquired over the last 12 months. The
company also operates infusion and respiratory services facilities,
specialty pharmacies and mail service facilities. Its Take Care
Health Systems subsidiary manages more than 750 in-store convenient
care clinics and worksite health and wellness centers.
January Comparable Sales and Prescriptions Filled
Calendar
Cough,
Flu
Shift
Generics
Cold, Flu
Shot
Actual
Impact
Impact
Impact
Impact
Total Comp Sales 2.9 % - 0.3 % - 0.9 % - 0.7 % - 0.3 %
Comp Front End 1.6 % - - - - Comp Rx Sales 3.7 % -
0.4 % - 1.3 % - 1.1 % - 0.5 % Comp Rx Scripts
- 0.8
%
*
- 0.4 % - - 1.4 % - 0.8 %
* Includes +2.4 percentage points from
patients filling more 90-day prescriptions
Please note: Sales numbers and the adjustments shown in the
table are preliminary, unaudited and subject to revision.
Comparable stores are defined as those drugstore locations open for
at least 12 consecutive months without closure for seven or more
consecutive days and without a major remodel or a natural disaster
in the past 12 months. Acquired operating locations and relocations
are not included as comparable stores for the first 12 months after
the acquisition or relocation.
Cautionary Note Regarding Forward-Looking Statements: Statements
in this release that are not historical are forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Words such as
"expect," “likely,” "outlook," “forecast,” "would," "could,"
"should," “can,” “will,” "project," "intend," "plan," "goal,”
“target,” “continue," "sustain," “synergy,” "on track," "believe,"
"seek," "estimate," "anticipate," "may," “possible,” "assume," and
variations of such words and similar expressions are intended to
identify such forward-looking statements. These forward-looking
statements are not guarantees of future performance and involve
risks, assumptions and uncertainties, including, but not limited
to, those described in Item 1A (Risk Factors) of our most recent
Annual Report on Form 10-K, which is incorporated herein by
reference, and in other documents that we file or furnish with the
Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those indicated or anticipated by such forward-looking
statements. Accordingly, you are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date they are made. Except to the extent required by law,
Walgreens does not undertake, and expressly disclaims, any duty or
obligation to update publicly any forward-looking statement after
the date of this release, whether as a result of new information,
future events, changes in assumptions or otherwise.
WalgreensMedia contact:Jim Graham, 847-315-2925orInvestor
contacts:Rick Hans, CFA, 847-315-2385Ashish Kohli, CFA,
847-315-3810http://news.walgreens.com@WalgreensNewsfacebook.com/Walgreens
West Africa Gold (NASDAQ:WAGI)
Historical Stock Chart
From Jul 2024 to Aug 2024
West Africa Gold (NASDAQ:WAGI)
Historical Stock Chart
From Aug 2023 to Aug 2024